ArticleFrontiers in medicine2026
Association of the total cholesterol-high-density lipoprotein-glucose index with metabolic-associated steatotic liver disease: a 5-year retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Current research on the relationship between the Total Cholesterol, High-Density Lipoprotein, and Glucose (CHG) index and the risk of Metabolic-Associated Steatotic Liver Disease (MASLD) is still limited. This study aims to explore the relationship between them and their predictive value in Chinese adults. Methods: A retrospective cohort analysis enrolled 6,274 individuals who received health assessments at Shenzhen Kuichong People's Hospital from 2018 to 2023. Cox proportional hazards regression analysis was implemented to evaluate associations between CHG and MASLD risk. Cox proportional hazards regression model with restricted cubic spline functions was utilized to assess potential non-linear associations. Additionally, ROC analysis evaluated CHG's predictive ability for MASLD. Results: Multivariable Cox regression showed that for each 0.1 unit increase in CHG, the HR for MASLD risk was 1.055 (95% CI: 1.030, 1.080). Non-linear association between them was identified, with inflection point at CHG = 5.42. Left of this inflection point, HR for CHG (per 0.1-unit)-MASLD association was 1.088 (95% CI: 1.055-1.122); right of this inflection point, the HR was 0.969 (95% CI: 0.912-1.029). Additionally, ROC curve analysis demonstrated that the AUC of CHG for predicting the 5-year risk of MASLD reached 0.678, which exceeded those of any single component indicator. When compared with TyG and FLI, CHG exhibited comparable predictive performance with no statistically significant differences. Time-dependent ROC analysis showed that within the 2.0-5-year period, the AUC of CHG remained between 0.656 and 0.678. Conclusion: This study indicates that increased CHG is independently positively associated with the risk of MASLD and exhibits a non-linear association. Reducing CHG values below 5.42 and implementing further reduction measures may significantly decrease the risk of MASLD. CHG exhibits certain predictive value for MASLD risk and has the potential to serve as an early identification marker for high-risk populations, providing a novel perspective for clinical prevention strategies of MASLD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.